Latest / The Dales Report | Trade to Black
CA Skip navigation Search Avatar image 0:41 / 15:28 Psychedelic Stock: Cybin Unveils Unprecedented 12-Month Results
Cybin (NYSE:CYBN) CEO Doug Drysdale, discusses the company’s groundbreaking results announced on Monday, November 18th. The key talking points included Cybin’s Phase 2 study of CYB003, a next-generation treatment for major depressive disorder (MDD). The study revealed extraordinary 12-month efficacy data, including 100% response rates and 71% remission among participants after just two 16 mg doses, administered three weeks apart. Cybin’s Chief Medical Officer, Amir Inamdar, described the results as “truly remarkable,” highlighting the treatment’s durable, sustained relief and significant…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.